Pharm Biol:网络药理学+实验验证研究枳实大黄汤治疗急性脑梗死的多靶点机制

2022-09-12 紫菀款冬 MedSci原创

枳实大黄汤(ZRS)是临床多年来用于治疗急性脑梗死(ACI)的中药配方。然而,确切的治疗机制仍不清楚。该研究通过网络药理学分析阐明ZRS对ACI作用的多靶点机制,并通过动物实验验证其作用。

目的:枳实大黄汤(ZRS)是临床多年来用于治疗急性脑梗死(ACI)的中药配方。然而,确切的治疗机制仍不清楚。该研究通过网络药理学分析阐明ZRS对ACI作用的多靶点机制,并通过动物实验验证其作用。

方法:采用网络药理学方法,研究了ZRS抗ACI的多组分、关键靶点和潜在机制。以ZRS的6个草药名称和“急性脑梗塞”作为关键词搜索相关数据库。此外,建立了MCAO模型,以验证网络药理学富集分析的结果。模型建立3h后,ZRS(10 g生药/kg)灌胃每天一次,连续7天。在ZRS处理后,进行TTC染色、Western blot分析、免疫组织化学和ELISA以进一步探讨ZRS干预ACI的机制。

结果:网络药理学方法确定69个涉及ZRS治疗ACI的关键靶点、10个核心基因和169个信号通路。动物体内实验表明,ZRS治疗显著减少脑梗死体积(42.76%)。还降低了AGE、RAGE和P65的表达水平;并抑制了炎症相关MMP-9和IFN-γ的表达。

结论:该研究结合网络药理学和动物实验,研究了ZRS治疗ACI的机制,首次阐明了ZRS的协同多组分和多靶点机制。同时验证了ZRS通过抑制AGE-RAGE通路的激活来减少神经炎症,从而对大鼠脑组织发挥保护作用,为ZRS治疗ACI的临床应用提供了理论依据

 

文献来源:

Shao Y, Zhang Y, Wu R, et al. Network pharmacology approach to investigate the multitarget mechanisms of Zhishi Rhubarb Soup on acute cerebral infarction. Pharm Biol. 2022;60(1):1394-1406. doi:10.1080/13880209.2022.2103718

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1787830, encodeId=f3ef1e8783094, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 06 04:10:05 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767930, encodeId=57ca1e67930b8, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Jan 16 06:10:05 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919498, encodeId=c44e1919498cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 30 11:10:05 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721967, encodeId=c1c21e21967bd, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Tue Oct 04 09:10:05 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465269, encodeId=b8901465269e6, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Tue Sep 13 13:10:05 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516205, encodeId=43ad15162056c, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Tue Sep 13 13:10:05 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
    2023-02-06 jj000001
  2. [GetPortalCommentsPageByObjectIdResponse(id=1787830, encodeId=f3ef1e8783094, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 06 04:10:05 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767930, encodeId=57ca1e67930b8, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Jan 16 06:10:05 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919498, encodeId=c44e1919498cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 30 11:10:05 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721967, encodeId=c1c21e21967bd, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Tue Oct 04 09:10:05 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465269, encodeId=b8901465269e6, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Tue Sep 13 13:10:05 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516205, encodeId=43ad15162056c, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Tue Sep 13 13:10:05 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1787830, encodeId=f3ef1e8783094, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 06 04:10:05 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767930, encodeId=57ca1e67930b8, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Jan 16 06:10:05 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919498, encodeId=c44e1919498cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 30 11:10:05 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721967, encodeId=c1c21e21967bd, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Tue Oct 04 09:10:05 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465269, encodeId=b8901465269e6, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Tue Sep 13 13:10:05 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516205, encodeId=43ad15162056c, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Tue Sep 13 13:10:05 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
    2023-03-30 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1787830, encodeId=f3ef1e8783094, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 06 04:10:05 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767930, encodeId=57ca1e67930b8, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Jan 16 06:10:05 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919498, encodeId=c44e1919498cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 30 11:10:05 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721967, encodeId=c1c21e21967bd, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Tue Oct 04 09:10:05 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465269, encodeId=b8901465269e6, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Tue Sep 13 13:10:05 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516205, encodeId=43ad15162056c, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Tue Sep 13 13:10:05 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
    2022-10-04 zhangph
  5. [GetPortalCommentsPageByObjectIdResponse(id=1787830, encodeId=f3ef1e8783094, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 06 04:10:05 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767930, encodeId=57ca1e67930b8, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Jan 16 06:10:05 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919498, encodeId=c44e1919498cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 30 11:10:05 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721967, encodeId=c1c21e21967bd, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Tue Oct 04 09:10:05 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465269, encodeId=b8901465269e6, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Tue Sep 13 13:10:05 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516205, encodeId=43ad15162056c, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Tue Sep 13 13:10:05 CST 2022, time=2022-09-13, status=1, ipAttribution=)]
    2022-09-13 karmond
  6. [GetPortalCommentsPageByObjectIdResponse(id=1787830, encodeId=f3ef1e8783094, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Feb 06 04:10:05 CST 2023, time=2023-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767930, encodeId=57ca1e67930b8, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Mon Jan 16 06:10:05 CST 2023, time=2023-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919498, encodeId=c44e1919498cb, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Mar 30 11:10:05 CST 2023, time=2023-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721967, encodeId=c1c21e21967bd, content=<a href='/topic/show?id=99474349903' target=_blank style='color:#2F92EE;'>#多靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43499, encryptionId=99474349903, topicName=多靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61333121812, createdName=zhangph, createdTime=Tue Oct 04 09:10:05 CST 2022, time=2022-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465269, encodeId=b8901465269e6, content=<a href='/topic/show?id=2dea8489010' target=_blank style='color:#2F92EE;'>#脑梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84890, encryptionId=2dea8489010, topicName=脑梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccf56689148, createdName=karmond, createdTime=Tue Sep 13 13:10:05 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516205, encodeId=43ad15162056c, content=<a href='/topic/show?id=7e868e9126b' target=_blank style='color:#2F92EE;'>#药理学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87912, encryptionId=7e868e9126b, topicName=药理学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=300b10929379, createdName=ms7019579240139182, createdTime=Tue Sep 13 13:10:05 CST 2022, time=2022-09-13, status=1, ipAttribution=)]

相关资讯

Plos Biol:遗传发育所在小头症发病机制研究中取得进展

WDR62基因突变是导致小头症的第二大主因,中国科学院遗传与发育生物学研究所许执恒研究组前期研究结果发现WDR62降低会导致神经前体细胞增殖减少,分化提前,并进一步导致神经元数量减少。然而,WDR62调控神经发生及大脑尺寸的分子机制依然不太清楚。

Nature:胰腺癌原来是这样“找饭吃”的!

肿瘤细胞在增殖、生长及转移过程中需要大量的能量供应。这一巨大的能量需求单单通过循环系统来输送远远不够,它需要借助巨噬细胞破坏其他正常细胞才能满足其自身的能量供应。

中药促进糖尿病创面愈合的信号通路

糖尿病伤口是糖尿病常见的慢性并发症之一,严重影响患者的生活质量,甚至导致致残和死亡。中药是我国特有的珍贵资源,具有良好的疗效和安全性。

STTT:中药天然化合物治疗缺血性脑卒中

中风与人类疾病中的第二大死亡原因和第三大残疾原因有关,而 IS 特别占所有中风病例的 80% 以上。由于人口的快速增长和老龄化,IS 发病率随着年龄的增长而急剧增加。

Oncogene:KNSTRN通过激活膀胱癌中的AKT来促进肿瘤的发生和吉西他滨的耐药性

KNSTRN是有丝分裂纺锤体的一个组成部分,在肿瘤发生中很少有研究。AKT通过调控各种底物的磷酸化,在肿瘤发生中起着重要作用。AKT的激活是由PTEN和PIP3调节的。

Genes Dev:研究揭示YAP/TAZ诱导AP-1有助于细胞增殖和器官生长

Yes相关蛋白 (YAP)及其同源的转录共激活因子PDZ-binding motif (TAZ)是控制细胞生长和器官大小的Hippo通路的关键效应因子,其失调会导致肿瘤发生或肥大。激活后,YAP/TA